NYSE:HLN News 4 December 2025 - 4 February 2026

Haleon PLC (LSE/NYSE: HLN) closed higher on 17 December 2025, rebounding after Tuesday’s dip. Here’s what’s moving the consumer-health giant behind Sensodyne, Panadol and Advil, including a Morgan Stanley upgrade, leadership changes effective 1 January 2026, and the next key date on the company calendar. Haleon PLC (HLN), the consumer health company behind household brands such as Sensodyne, Panadol, Advil, Centrum, Voltaren and Theraflu, ended Wednesday’s session higher in London, as investors balanced near-term market noise against a string of “positioning” catalysts that have kept the stock in focus into year-end. London South East+2Hargreaves Lansdown+2 While there was no new

Updated: December 4, 2025 Haleon PLC – the consumer‑health group behind Sensodyne, Voltaren, Advil, Panadol and Centrum – is ending 2025 in a strangely paradoxical place: the business is grinding out steady growth and strong cash flow, while the share price has been drifting lower in recent weeks. As of early trading on December 4, 2025, Haleon’s New York‑listed ADR (NYSE: HLN) is changing hands around $9.5 per share, implying a market cap in the mid‑$40 billion range. MarketBeat On the London Stock Exchange (LSE: HLN), the stock closed at £3.61 on Wednesday, December 3, down 2.09% on the day